Holen Sie sich die Stockscreener-App
12.83
0.31%
-0.04
Schlusskurs vom Vortag:
$12.87
Offen:
$12.8
24-Stunden-Volumen:
1.36M
Relative Volume:
0.53
Marktkapitalisierung:
$4.09B
Einnahmen:
$3.05B
Nettoeinkommen (Verlust:
$181.32M
KGV:
34.33
EPS:
0.3737
Netto-Cashflow:
$225.64M
1W Leistung:
+2.48%
1M Leistung:
+0.94%
6M Leistung:
+18.58%
1J Leistung:
+65.76%
1-Tages-Spanne:
$12.38
$12.95
1-Wochen-Bereich:
$12.38
$13.03
52-Wochen-Spanne:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.83 | 4.09B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.62 | 52.51B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
114.16 | 48.01B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.38 | 41.69B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.95 | 40.70B | 17.52B | 1.58B | 1.06B | 1.3428 |
UTHR
United Therapeutics Corp
|
570.40 | 24.21B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | UBS | Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
3 Biotech Stocks to Watch for Respectable Growth Beyond AI - AOL.com
Artemis Investment Management LLP Buys Shares of 124,899 Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Amneal (AMRX) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings Scheduled For May 1, 2026 - Benzinga
UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook - Yahoo Finance
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Amneal Q1 2026 slides: $750M Kashiv deal creates biosimilar leader - Investing.com India
Earnings call transcript: Amneal Pharma Q1 2026 beats EPS forecast By Investing.com - Investing.com India
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge? - simplywall.st
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Amneal (AMRX) Q1 Earnings Report Preview: What To Look For - StockStory
Amneal Pharma to acquire Kashiv BioSciences to create fully integrated global biosimilar leader - MSN
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals (AMRX) is a top-ranked momentum stock: Should you buy? - MSN
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - Yahoo Finance
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
AMRX Should I Buy - Intellectia AI
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 - Quantisnow
Amneal 2026-2027 Upside From Biosimilars Scale - Zacks Investment Research
AMRX Valuation: What 1.69x Sales Means for Investors - Yahoo Finance
AMRX Growth Drivers: Generics, Biosimilars, and Crexont - Yahoo Finance
BlackRock (NYSE: AMRX) holds 24.1M shares, 7.6% stake reported - Stock Titan
Amneal initiates nationwide settlement for opioid-related claims - MSN
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown - Yahoo Finance
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):